Alaunos Therapeutics, Inc. TCRT
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -9.13% | 18.28% | |||
| Gross Profit | 9.13% | -19.27% | |||
| SG&A Expenses | -3.59% | 6.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.93% | 11.21% | |||
| Operating Income | 5.93% | -11.58% | |||
| Income Before Tax | 5.37% | -12.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.37% | -12.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.37% | -12.65% | |||
| EBIT | 5.93% | -11.58% | |||
| EBITDA | 6.08% | -10.90% | |||
| EPS Basic | 24.17% | -20.21% | |||
| Normalized Basic EPS | 24.17% | -34.46% | |||
| EPS Diluted | 24.17% | -20.21% | |||
| Normalized Diluted EPS | 24.17% | -34.46% | |||
| Average Basic Shares Outstanding | 24.80% | -16.23% | |||
| Average Diluted Shares Outstanding | 24.80% | -16.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||